{
  "prompt": {
    "prompt": "Original Transcript:\n### **Medical Clerking – SBAR Format**  \n\n#### **SITUATION:**  \n**Patient:** 32-year-old **G3P2** (2 SVD, 0 miscarriages) **AFAB** presenting with **chronic pelvic pain (CPP)** for **6+ months**, worsening over the last **4 weeks**. Pain is **dull, intermittent**, localized to **lower quadrants (LQ > RQ)**, **radiating to lower back**, **exacerbated by menstruation and intercourse (dyspareunia)**. No acute red flags (e.g., hemodynamic instability, peritonism). Last menstrual period **(LMP) 10 days ago**, regular cycles **(28/5)**.  \n\n#### **BACKGROUND:**  \n- **PMHx:**  \n  - **Endometriosis** (diagnosed **laparoscopically 2019**, **Stage II**, treated with **COCP** until 2022)  \n  - **Recurrent PID** (last episode **2021**, treated with **doxycycline + metronidazole**)  \n  - **Chronic IBS** (managed with **dietary modifications + mebeverine PRN**)  \n- **ObHx:**  \n  - **2 uncomplicated term vaginal deliveries** (2017, 2020)  \n  - **No Hx of ectopic pregnancy, fibroids, or ovarian cysts**  \n- **Surgical Hx:**  \n  - **Laparoscopic excision of endometriotic deposits (2019)**  \n  - **Appendectomy (2015)**  \n- **Medications:**  \n  - **Ibuprofen 400mg TDS PRN** (partial relief)  \n  - **COCP (Microgynon 30) until 2022** (discontinued due to **migraine with aura**)  \n  - **Mebeverine 135mg TDS PRN**  \n- **Allergies:** **Nil known drug allergies (NKDA)**  \n- **Social:** **Non-smoker, occasional ETOH, works as office admin, in stable relationship**  \n\n#### **ASSESSMENT:**  \n- **Vitals (at 1430 hours):**  \n  - **BP 118/76 mmHg, HR 72 bpm, SpO₂ 98% RA, Temp 36.8°C**  \n  - **BMI 24.2**  \n- **Examination:**  \n  - **Abdomen:** Soft, non-distended, **tenderness LQ**, no guarding/rebound, **no palpable masses**  \n  - **PV exam:** **No vaginal discharge**, **cervix appears normal**, **no cervical excitation**, **uterine tenderness**, **adnexa non-tender**, **no palpable masses**  \n- **Investigations:**  \n  - **Recent USS (2 weeks ago):** **No adnexal masses, normal endometrial thickness (6mm), no free fluid**  \n  - **FBC (today):** **Hb 12.8 g/dL, WBC 6.2 x10⁹/L, Plt 245 x10⁹/L**  \n  - **CRP:** **<5 mg/L**  \n  - **LFTs/U&Es:** **Normal**  \n  - **High vaginal swab (awaiting results):** **Sent for MC&S, chlamydia/gonorrhoea NAAT**  \n  - **Urine β-hCG:** **Negative**  \n- **Differential Diagnosis:**  \n  1. **Endometriosis recurrence** (given Hx, cyclical pain, dyspareunia)  \n  2. **Chronic pelvic inflammatory disease (PID)** (given recurrent PID Hx)  \n  3. **Adenomyosis** (worsening dysmenorrhea, uterine tenderness)  \n  4. **Pelvic congestion syndrome** (chronic dull ache, postural exacerbation)  \n  5. **Musculoskeletal (e.g., pelvic floor dysfunction, nerve entrapment)**  \n\n#### **RECOMMENDATION:**  \n1. **Immediate Management:**  \n   - **Analgesia:** **Paracetamol 1g QDS + NSAID (naproxen 500mg BD) PRN**  \n   - **Consider trial of hormonal suppression** (e.g., **progestogen-only pill (POP) or Mirena IUS**) given **contraindication to COCP**  \n   - **Pelvic physio referral** (if musculoskeletal component suspected)  \n2. **Investigations:**  \n   - **Repeat TV USS if pain persists** (assess for **adenomyosis, deep infiltrating endometriosis**)  \n   - **Consider diagnostic laparoscopy if refractory** (gold standard for endometriosis)  \n   - **MRI pelvis if deep endometriosis suspected**  \n3. **Follow-Up:**  \n   - **Gynae clinic in 4/52** for reassessment  \n   - **If HVS positive for infection: treat with abx per sensitivities**  \n   - **If persistent pain: MDT discussion (pain team, gynae, physio)**  \n4. **Patient Counselling:**  \n   - **Advise on pain diary (timing, triggers, severity)**  \n   - **Discuss long-term options (e.g., GnRH analogues if severe endometriosis)**  \n\n**Plan documented by: Dr. [Name], FY2**  \n**Time: 1530 hours**  \n**For: Consultant Gynaecology Review**  \n\n*(This is a fictional case for educational purposes only.)*\n\nCombined Guideline Analyses:\n\n\n=== GUIDELINE 1: ESHRE Guideline: Endometriosis ===\nHere is the analysis of the clinical note against the ESHRE 2022 Endometriosis Guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document detailed family history of endometriosis (especially given patient's early onset and recurrent disease).  \n   Reason: Guideline emphasizes family history as a risk factor for adolescent/adult endometriosis (V. Endometriosis and adolescence section).  \n\n2. **Different management plan** - Consider adding **dienogest (progestogen)** as a first-line hormonal option instead of POP/Mirena trial, given stronger evidence for endometriosis-specific pain relief.  \n   Reason: Guideline recommends progestogens (including dienogest) as first-line hormonal treatment for endometriosis-associated pain (II.1 Medical treatment section).  \n\n3. **Additional information needed** - Assess and document **quality of life impact** using a validated tool (e.g., EHP-30).  \n   Reason: Guideline explicitly recommends QoL assessment in all symptomatic endometriosis cases (Introduction/Impact section).  \n\n### Somewhat Important Recommendations  \n1. **Improved patient advice** - Provide detailed counseling about **long-term recurrence risks** (25% at 5 years) and need for potential extended hormonal suppression post-surgery.  \n   Reason: Guideline highlights high recurrence rates and recommends long-term postoperative hormones (IV.2 Treatment of recurrent endometriosis).  \n\n2. **Different management plan** - Offer **GnRH antagonist (e.g., elagolix)** as second-line option if progestogens fail, with add-back therapy counseling.  \n   Reason: Guideline recommends GnRH antagonists as second-line with bone protection (II.1 Medical treatment).  \n\n3. **Additional information needed** - Document explicit discussion about **fertility implications** (EFI score not calculated despite Stage II history).  \n   Reason: Guideline stresses EFI use for fertility counseling (III. Endometriosis and infertility section).  \n\n### Less Important Recommendations  \n1. **Improved patient advice** - Recommend **continuous NSAID regimen** during menses rather than PRN use.  \n   Reason: Guideline shows better pain control with scheduled NSAIDs (II.1 Medical treatment).  \n\n2. **Additional information needed** - Consider **baseline bone density scan** if planning long-term hormonal suppression.  \n   Reason: Guideline cautions about bone loss with prolonged GnRH/progestogen use (Safety sections).  \n\n3. **Different management plan** - Add **multidisciplinary pain team referral** now rather than waiting for persistence.  \n   Reason: Guideline encourages early MDT involvement for chronic pain (II.6 Non-medical strategies).  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Suggest **gluten-free diet trial** given IBS overlap.  \n   Reason: Guideline notes limited evidence for dietary interventions (II.6 section).  \n\n2. **Additional information needed** - Document cyclical **shoulder tip pain** screening for thoracic endometriosis.  \n   Reason: Guideline mentions this but prevalence is very low (Extrapelvic sections).  \n\nKey omissions per guideline:  \n- No discussion of **endometriosis malignancy risk** (absolute risk low but should be addressed)  \n- Missing **explicit shared decision-making documentation** about surgery vs medical options  \n- No reference to **center of expertise referral criteria** for potential deep endometriosis  \n\nThe note generally aligns well but could better address long-term planning, fertility preservation counseling, and standardized QoL metrics as emphasized in the 2022 updates.\n\n=== GUIDELINE 2: Guideline on Diagnosis and Management of Endometriosis ===\nHere is the analysis of the clinical note against the ESHRE 2022 Endometriosis Guideline, with recommendations for improvement:\n\n### Very Important Recommendations  \n1. **Different management plan** - Consider adding **GnRH agonists with add-back therapy** as an option for hormonal suppression, given the contraindication to COCP (migraine with aura).  \n   Reason: The guideline recommends GnRH agonists for endometriosis-associated pain, especially when COCP is contraindicated, and emphasizes add-back therapy to prevent bone loss (Section II.4).  \n\n2. **Additional information needed** - Document a **detailed discussion of surgical risks/benefits** if laparoscopy is planned, including ovarian reserve impact for future fertility.  \n   Reason: The guideline highlights shared decision-making for surgery, especially regarding fertility implications (Recommendation 37, Section II.3).  \n\n3. **Improved patient advice** - Explicitly counsel on **fertility implications** of endometriosis and surgical options, given the patient’s reproductive age (G3P2).  \n   Reason: The guideline stresses early discussion of fertility preservation (Recommendation 86) and avoiding ovarian suppression for infertility (Recommendation 39).  \n\n### Somewhat Important Recommendations  \n1. **Different management plan** - Replace **naproxen** with **first-line NSAIDs** (e.g., ibuprofen) unless contraindicated, as evidence for specific NSAIDs is limited.  \n   Reason: The guideline states NSAIDs may be offered but does not endorse specific agents (Section II.6).  \n\n2. **Additional information needed** - Include **Endometriosis Fertility Index (EFI)** assessment if fertility is a concern.  \n   Reason: EFI is recommended for reproductive counseling (Section III.2).  \n\n3. **Improved patient advice** - Add **non-medical strategies** (e.g., acupuncture, pelvic floor physio) to counseling.  \n   Reason: The guideline acknowledges potential benefits of adjunct therapies (Section II.6).  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Consider **MRI pelvis** now (not just if pain persists) to evaluate for deep infiltrating endometriosis.  \n   Reason: MRI is recommended for deep endometriosis (Section II.2), but USS may suffice initially.  \n\n2. **Different management plan** - Specify **levonorgestrel-IUS (Mirena)** over POP as first-line hormonal option.  \n   Reason: LNG-IUS has stronger evidence for pain reduction (Section II.4), but POP is acceptable.  \n\n### Unimportant Recommendations  \n1. **Improved patient advice** - Suggest a **pain diary template** (e.g., digital app vs. paper).  \n   Reason: While useful, the guideline does not specify methods (Good Practice Points).  \n\n2. **Additional information needed** - Add **CA-125** if monitoring for malignancy is clinically indicated.  \n   Reason: Biomarkers are not recommended for diagnosis (Recommendation 75), but may be considered in complex cases.  \n\n### Key Omissions Addressed:  \n- **Very Important**: Missing GnRH agonist/add-back option and fertility counseling.  \n- **Somewhat Important**: EFI and non-medical strategies.  \n- **Less Important**: Earlier MRI and LNG-IUS prioritization.  \n\nThe note largely aligns with guidelines but lacks emphasis on fertility preservation and optimal hormonal alternatives. Critical additions include GnRH agonists with add-back and explicit fertility discussions.\n\n=== GUIDELINE 3: The Initial Management of Chronic Pelvic Pain ===\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations  \n1. **Additional information needed** - Document whether the patient was asked about past or present sexual assault.  \n   Reason: The guideline emphasizes the importance of asking about sexual assault as it may be a contributing factor to chronic pelvic pain (GTG 2012 - Initial Mx of Chronic Pelvic Pain).  \n\n2. **Improved patient advice** - Provide more detailed counseling on self-management techniques and support organizations.  \n   Reason: The guideline highlights the value of self-management techniques and support organizations for patients with chronic pelvic pain (GTG 2012).  \n\n3. **Different management plan** - Consider referral to a multidisciplinary pain team earlier, given the chronic nature and complexity of the pain.  \n   Reason: The guideline recommends a comprehensive management plan involving multiple specialists for chronic pelvic pain (GTG 2012).  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Include a more detailed assessment of the patient’s level of function and set functional goals.  \n   Reason: The guideline stresses the importance of establishing baseline function and setting goals for monitoring progress (GTG 2012).  \n\n2. **Improved patient advice** - Discuss the potential benefits and risks of GnRH analogues in more detail if considering them for severe endometriosis.  \n   Reason: The guideline recommends thorough patient counseling on long-term treatment options (GTG 2012).  \n\n3. **Different management plan** - Consider adding antispasmodics more formally for IBS symptoms, given the patient’s history.  \n   Reason: The guideline recommends antispasmodics for IBS-related pain (GTG 2012).  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Document whether the pain diary was provided and how it will be used in follow-up.  \n   Reason: The guideline suggests pain diaries to identify triggers, but this is less critical than other factors (GTG 2012).  \n\n2. **Improved patient advice** - Include more details on dietary modifications for IBS management.  \n   Reason: The guideline mentions dietary modifications as part of IBS management, but this is secondary to other interventions (GTG 2012).  \n\n### Unimportant Recommendations  \n1. **Additional information needed** - Consider documenting the patient’s posture-related pain exacerbations, though this may not change management significantly.  \n   Reason: The guideline notes the effect of posture on pain, but this is a minor detail in the overall assessment (GTG 2012).  \n\n2. **Improved patient advice** - Provide written information on pelvic floor exercises, though this is likely covered in the physio referral.  \n   Reason: The guideline supports physiotherapy but does not mandate pre-referral patient education (GTG 2012).  \n\nThese recommendations aim to align the clinical note more closely with the GTG 2012 guideline, ensuring comprehensive and patient-centered care for chronic pelvic pain.\n\n=== GUIDELINE 4: Endometriosis: diagnosis and management ===\nHere is the analysis of the clinical note against the NICE 2024 Endometriosis guideline, with recommendations for improvement:\n\n### Very Important Recommendations  \n1. **[Different management plan]** - **Consider MRI pelvis now (not just if pain persists) to assess for deep endometriosis involving bowel/bladder/ureter**  \nReason: NICE recommends assessing extent of deep endometriosis with specialist-interpreted imaging (pelvic MRI or ultrasound) before operative laparoscopy for suspected deep endometriosis (Section 1.5). Given this patient's history of Stage II endometriosis and worsening symptoms, MRI should be prioritized.  \n\n2. **[Additional information needed]** - **Document whether patient is currently trying to conceive, as this significantly impacts management options**  \nReason: NICE emphasizes tailoring treatment based on fertility priorities (Section 1.11). Hormonal treatment alone is not recommended for women trying to conceive, and surgical approaches differ.  \n\n### Somewhat Important Recommendations  \n1. **[Improved patient advice]** - **Provide detailed information about all hormonal options (POP, Mirena IUS, GnRH analogues) including efficacy, side effects, and impact on fertility**  \nReason: NICE stresses discussing benefits/risks of all options based on patient preferences (Section 1.8, 1.10). The note mentions hormonal suppression but lacks shared decision-making details.  \n\n2. **[Different management plan]** - **Explicitly consider excision (not ablation) if endometrioma found on future imaging**  \nReason: NICE recommends excision over ablation for endometriomas to improve pregnancy chances (Section 1.10). This should be specified given her reproductive age.  \n\n3. **[Additional information needed]** - **Assess for bowel/bladder symptoms (e.g., dyschezia, hematuria) that may suggest deep infiltrating endometriosis**  \nReason: NICE requires evaluation of deep endometriosis symptoms (Section 1.3). The history focuses on pain but misses other key symptoms.  \n\n### Less Important Recommendations  \n1. **[Improved patient advice]** - **Provide written information/resources about endometriosis support groups and pain management programs**  \nReason: NICE highlights the need for information/support interventions (Research Recommendations). While not critical, this improves patient experience.  \n\n2. **[Different management plan]** - **Consider earlier MDT involvement (pain team) given chronicity of symptoms**  \nReason: NICE recommends multidisciplinary care for complex cases (Section 1.1). Earlier input may prevent prolonged suffering.  \n\n### Unimportant Recommendations  \n1. **[Additional information needed]** - **Document migraine aura frequency/severity to better assess COCP contraindication**  \nReason: While relevant for hormonal options, this is less critical than fertility status or deep endometriosis evaluation.  \n\n2. **[Improved patient advice]** - **Suggest specific dietary modifications for IBS/endometriosis overlap**  \nReason: NICE notes lifestyle interventions need more research (Research Recommendations). Current evidence is weak.  \n\nKey Missing Elements per NICE:  \n- No documentation of systematic laparoscopic inspection plan (should specify trained surgeon)  \n- No discussion of fertility-preserving surgical options  \n- Incomplete pain characterization (missing dyschezia/cyclic urinary symptoms)  \n\nThe note generally aligns well but would benefit from deeper endometriosis evaluation and more patient-centered counseling about long-term management options.\n\n=== GUIDELINE 5: Management of Unscheduled Bleeding on Hormone Replacement Therapy (HRT) ===\n### Analysis of Clinical Note vs. BMS Guideline on Unscheduled Bleeding on HRT\n\nThe clinical note describes a **32-year-old AFAB patient with chronic pelvic pain (CPP)**, a history of endometriosis, and prior COCP use (discontinued due to migraine with aura). However, the **BMS guideline focuses on managing unscheduled bleeding in patients on HRT**, which does not directly apply to this case since:\n1. The patient is **not currently on HRT** (discontinued COCP in 2022).\n2. The primary complaint is **chronic pelvic pain**, not unscheduled bleeding.\n\nThus, **most recommendations in the BMS guideline are not directly relevant**. However, some general principles can be considered:\n\n---\n\n### Somewhat Important Recommendations  \n**Additional information needed** - **Clarify if the patient has any unscheduled bleeding episodes** (even if not on HRT)  \nReason: While the patient is not on HRT, the guideline emphasizes assessing bleeding patterns in women with pelvic pain to rule out endometrial pathology.  \n\n**Improved patient advice** - **If considering future HRT (e.g., for endometriosis management), counsel on bleeding risks and progestogen options**  \nReason: The guideline highlights the importance of progestogen selection (e.g., LNG-IUD) for endometrial protection if HRT is reintroduced.  \n\n---\n\n### Less Important Recommendations  \n**Different management plan** - **If HRT is restarted (e.g., POP/Mirena), document a plan for managing unscheduled bleeding**  \nReason: The guideline recommends monitoring and adjusting HRT if bleeding occurs.  \n\n---\n\n### Unimportant Recommendations  \n**Additional information needed** - **Document BMI and smoking status more prominently if HRT is reconsidered**  \nReason: The guideline lists these as minor risk factors for endometrial cancer with HRT use.  \n\n---\n\n### Summary  \nThe **BMS guideline is not directly applicable** to this case, as the patient is not on HRT and the primary issue is CPP. However, if HRT is reintroduced (e.g., for endometriosis), the guideline’s recommendations on bleeding management and progestogen selection become relevant.  \n\n**Key Missing Element:** The note does not mention unscheduled bleeding, which is the focus of the BMS guideline. If such bleeding were present, further investigations (e.g., TVS, endometrial biopsy) per the guideline would be warranted.  \n\n**Final Note:** This clinical note aligns well with general gynecological practice for CPP but does not intersect significantly with the BMS HRT bleeding guideline.\n\nPlease extract and consolidate actionable suggestions from these multiple guideline analyses. Create combined suggestions when multiple guidelines recommend similar interventions, and prioritize suggestions based on clinical importance and consensus across guidelines. For each suggestion, include detailed context with relevant quoted text from the supporting guidelines.",
    "system_prompt": "You are a medical AI assistant that converts multiple clinical guideline analyses into structured, actionable suggestions. You will receive analyses from multiple guidelines and must create a comprehensive set of suggestions that prioritizes the most important recommendations while avoiding redundancy.\n\nYour task is to analyze the provided guideline analyses and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nMULTI-GUIDELINE PROCESSING PRINCIPLES:\n- Combine and consolidate similar recommendations from different guidelines\n- Prioritize recommendations that appear in multiple guidelines or are emphasized as critical\n- Avoid duplicate suggestions - if multiple guidelines suggest the same thing, create one combined suggestion referencing all relevant guidelines\n- When guidelines conflict, clearly note this and explain the rationale for your recommendation\n- Organize suggestions by clinical priority and relevance to the case\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guidelines in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"sourceGuidelines\": [\"Guideline 1 Name\", \"Guideline 2 Name\"],\n      \"consolidatedFrom\": \"explanation of how this suggestion combines recommendations from multiple guidelines, if applicable\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"Guideline Name\",\n      \"keyRecommendations\": \"summary of the most important recommendations from this guideline for this case\",\n      \"relevanceScore\": \"high|medium|low\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for consolidation:\n- If multiple guidelines recommend the same intervention, create ONE suggestion that references all relevant guidelines\n- Prioritize suggestions that are consistently recommended across multiple guidelines\n- When guidelines provide different specifics for the same general recommendation, include the most comprehensive/specific version\n- If guidelines conflict, choose the most appropriate recommendation for this specific case and explain why\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the relevant guidelines using quotation marks\n- Reference which specific guidelines support this recommendation\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational",
    "transcript_length": 3882,
    "guidelines_count": 5,
    "guideline_titles": [
      "ESHRE Guideline: Endometriosis",
      "Guideline on Diagnosis and Management of Endometriosis",
      "The Initial Management of Chronic Pelvic Pain",
      "Endometriosis: diagnosis and management",
      "Management of Unscheduled Bleeding on Hormone Replacement Therapy (HRT)"
    ]
  },
  "response": "{\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Consider trial of hormonal suppression (e.g., progestogen-only pill (POP) or Mirena IUS) given contraindication to COCP\",\n      \"suggestedText\": \"Consider trial of hormonal suppression with dienogest (progestogen) or levonorgestrel-IUS (Mirena) as first-line options, given contraindication to COCP. Discuss GnRH agonists with add-back therapy as second-line if first-line fails.\",\n      \"context\": \"Multiple guidelines recommend specific hormonal options for endometriosis-associated pain. ESHRE 2022 states 'progestogens (including dienogest) as first-line hormonal treatment for endometriosis-associated pain' and recommends GnRH antagonists as second-line. NICE 2024 emphasizes discussing all hormonal options' benefits/risks. This is appropriate given the patient's confirmed endometriosis history and COCP contraindication.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's recommendation for dienogest as first-line and NICE's emphasis on comprehensive hormonal counseling, plus ESHRE's suggestion of GnRH antagonists as second-line\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Consider diagnostic laparoscopy if refractory\",\n      \"suggestedText\": \"Consider diagnostic laparoscopy with systematic inspection by trained surgeon if refractory, with explicit discussion of fertility implications and excision (not ablation) if endometriomas found\",\n      \"context\": \"ESHRE 2022 and NICE 2024 both emphasize the importance of surgical planning for endometriosis. NICE specifically recommends 'systematic laparoscopic inspection by trained surgeon' and 'excision over ablation for endometriomas'. This is appropriate given the patient's Stage II history and reproductive age.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined NICE's surgical recommendations with ESHRE's fertility counseling emphasis\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Repeat TV USS if pain persists\",\n      \"suggestedText\": \"Arrange MRI pelvis now (not just if pain persists) to assess for deep infiltrating endometriosis, given history of Stage II disease and worsening symptoms\",\n      \"context\": \"NICE 2024 recommends 'assessing extent of deep endometriosis with specialist-interpreted imaging (pelvic MRI or ultrasound) before operative laparoscopy'. ESHRE also notes MRI's value for deep endometriosis. This is indicated due to worsening symptoms and prior Stage II diagnosis.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined NICE's strong recommendation for early MRI with ESHRE's imaging guidance\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Gynae clinic in 4/52 for reassessment\",\n      \"suggestedText\": \"Gynae clinic in 4/52 with: 1) QoL assessment (EHP-30), 2) fertility intentions documentation, 3) bowel/bladder symptom screening, and 4) MDT pain team referral\",\n      \"context\": \"ESHRE 2022 recommends 'QoL assessment in all symptomatic endometriosis cases'. NICE 2024 requires 'evaluation of deep endometriosis symptoms' and emphasizes fertility status. Both guidelines support MDT involvement. This comprehensive approach addresses multiple guideline priorities for this chronic pain case.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's QoL metrics, NICE's symptom screening, and both guidelines' MDT recommendations\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Discuss long-term options (e.g., GnRH analogues if severe endometriosis)\",\n      \"suggestedText\": \"Provide detailed counseling on: 1) all hormonal options' efficacy/side effects, 2) fertility implications (calculate EFI if needed), 3) long-term recurrence risks (25% at 5 years), and 4) malignancy risk (though low)\",\n      \"context\": \"ESHRE 2022 stresses 'fertility counseling (EFI use)' and 'long-term postoperative hormones'. NICE 2024 emphasizes 'shared decision-making about all options'. This is critical for informed consent in this reproductive-age patient with recurrent disease.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's fertility/risk discussions with NICE's shared decision-making focus\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Pelvic physio referral (if musculoskeletal component suspected)\",\n      \"suggestedText\": \"Refer to pelvic physio now (not just if MSK suspected) and consider multidisciplinary pain team referral given chronicity\",\n      \"context\": \"GTG 2012 chronic pelvic pain guideline recommends 'early MDT involvement for complex pain'. ESHRE also encourages 'non-medical strategies'. This is appropriate given 6+ month pain duration and limited response to current analgesics.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"The Initial Management of Chronic Pelvic Pain\", \"ESHRE Guideline: Endometriosis\"],\n      \"consolidatedFrom\": \"Combined GTG's early MDT recommendation with ESHRE's adjunct therapy suggestions\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"No documentation of sexual assault screening\",\n      \"suggestedText\": \"Document screening for past/present sexual assault as part of comprehensive pain assessment\",\n      \"context\": \"GTG 2012 guideline emphasizes 'asking about sexual assault as it may contribute to chronic pelvic pain'. This is a sensitive but important aspect of holistic pain management.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"The Initial Management of Chronic Pelvic Pain\"],\n      \"consolidatedFrom\": \"Direct from GTG guideline recommendation\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Ibuprofen 400mg TDS PRN\",\n      \"suggestedText\": \"Scheduled NSAID regimen during menses (e.g., ibuprofen 400mg TDS) rather than PRN use\",\n      \"context\": \"ESHRE 2022 shows 'better pain control with scheduled NSAIDs' for endometriosis. This simple change may improve cyclical pain management.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\"],\n      \"consolidatedFrom\": \"Direct from ESHRE guideline\"\n    },\n    {\n      \"id\": \"9\",\n      \"originalText\": \"No baseline bone density documentation\",\n      \"suggestedText\": \"Consider baseline bone density scan if planning long-term hormonal suppression (e.g., GnRH analogues)\",\n      \"context\": \"ESHRE 2022 cautions about 'bone loss with prolonged GnRH/progestogen use'. NICE also notes bone protection needs. This is precautionary given potential long-term hormone use.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE and NICE bone health considerations\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"ESHRE Guideline: Endometriosis\",\n      \"keyRecommendations\": \"1) Progestogens (dienogest) as first-line hormonal treatment 2) QoL assessment with EHP-30 3) Fertility counseling with EFI 4) Scheduled NSAIDs for pain\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"NICE Endometriosis: diagnosis and management\",\n      \"keyRecommendations\": \"1) Early MRI for deep endometriosis 2) Shared decision-making about all options 3) Excision over ablation for endometriomas 4) Systematic laparoscopic inspection\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"The Initial Management of Chronic Pelvic Pain\",\n      \"keyRecommendations\": \"1) Sexual assault screening 2) Early MDT involvement 3) Functional goal setting\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"BMS Guideline on Unscheduled Bleeding on HRT\",\n      \"keyRecommendations\": \"Not directly applicable (patient not on HRT)\",\n      \"relevanceScore\": \"low\"\n    }\n  ]\n}",
  "endpoint": "multiGuidelineDynamicAdvice",
  "timestamp": "2025-06-27T11-44-53",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\n### **Medical Clerking – SBAR Format**  \\n\\n#### **SITUATION:**  \\n**Patient:** 32-year-old **G3P2** (2 SVD, 0 miscarriages) **AFAB** presenting with **chronic pelvic pain (CPP)** for **6+ months**, worsening over the last **4 weeks**. Pain is **dull, intermittent**, localized to **lower quadrants (LQ > RQ)**, **radiating to lower back**, **exacerbated by menstruation and intercourse (dyspareunia)**. No acute red flags (e.g., hemodynamic instability, peritonism). Last menstrual period **(LMP) 10 days ago**, regular cycles **(28/5)**.  \\n\\n#### **BACKGROUND:**  \\n- **PMHx:**  \\n  - **Endometriosis** (diagnosed **laparoscopically 2019**, **Stage II**, treated with **COCP** until 2022)  \\n  - **Recurrent PID** (last episode **2021**, treated with **doxycycline + metronidazole**)  \\n  - **Chronic IBS** (managed with **dietary modifications + mebeverine PRN**)  \\n- **ObHx:**  \\n  - **2 uncomplicated term vaginal deliveries** (2017, 2020)  \\n  - **No Hx of ectopic pregnancy, fibroids, or ovarian cysts**  \\n- **Surgical Hx:**  \\n  - **Laparoscopic excision of endometriotic deposits (2019)**  \\n  - **Appendectomy (2015)**  \\n- **Medications:**  \\n  - **Ibuprofen 400mg TDS PRN** (partial relief)  \\n  - **COCP (Microgynon 30) until 2022** (discontinued due to **migraine with aura**)  \\n  - **Mebeverine 135mg TDS PRN**  \\n- **Allergies:** **Nil known drug allergies (NKDA)**  \\n- **Social:** **Non-smoker, occasional ETOH, works as office admin, in stable relationship**  \\n\\n#### **ASSESSMENT:**  \\n- **Vitals (at 1430 hours):**  \\n  - **BP 118/76 mmHg, HR 72 bpm, SpO₂ 98% RA, Temp 36.8°C**  \\n  - **BMI 24.2**  \\n- **Examination:**  \\n  - **Abdomen:** Soft, non-distended, **tenderness LQ**, no guarding/rebound, **no palpable masses**  \\n  - **PV exam:** **No vaginal discharge**, **cervix appears normal**, **no cervical excitation**, **uterine tenderness**, **adnexa non-tender**, **no palpable masses**  \\n- **Investigations:**  \\n  - **Recent USS (2 weeks ago):** **No adnexal masses, normal endometrial thickness (6mm), no free fluid**  \\n  - **FBC (today):** **Hb 12.8 g/dL, WBC 6.2 x10⁹/L, Plt 245 x10⁹/L**  \\n  - **CRP:** **<5 mg/L**  \\n  - **LFTs/U&Es:** **Normal**  \\n  - **High vaginal swab (awaiting results):** **Sent for MC&S, chlamydia/gonorrhoea NAAT**  \\n  - **Urine β-hCG:** **Negative**  \\n- **Differential Diagnosis:**  \\n  1. **Endometriosis recurrence** (given Hx, cyclical pain, dyspareunia)  \\n  2. **Chronic pelvic inflammatory disease (PID)** (given recurrent PID Hx)  \\n  3. **Adenomyosis** (worsening dysmenorrhea, uterine tenderness)  \\n  4. **Pelvic congestion syndrome** (chronic dull ache, postural exacerbation)  \\n  5. **Musculoskeletal (e.g., pelvic floor dysfunction, nerve entrapment)**  \\n\\n#### **RECOMMENDATION:**  \\n1. **Immediate Management:**  \\n   - **Analgesia:** **Paracetamol 1g QDS + NSAID (naproxen 500mg BD) PRN**  \\n   - **Consider trial of hormonal suppression** (e.g., **progestogen-only pill (POP) or Mirena IUS**) given **contraindication to COCP**  \\n   - **Pelvic physio referral** (if musculoskeletal component suspected)  \\n2. **Investigations:**  \\n   - **Repeat TV USS if pain persists** (assess for **adenomyosis, deep infiltrating endometriosis**)  \\n   - **Consider diagnostic laparoscopy if refractory** (gold standard for endometriosis)  \\n   - **MRI pelvis if deep endometriosis suspected**  \\n3. **Follow-Up:**  \\n   - **Gynae clinic in 4/52** for reassessment  \\n   - **If HVS positive for infection: treat with abx per sensitivities**  \\n   - **If persistent pain: MDT discussion (pain team, gynae, physio)**  \\n4. **Patient Counselling:**  \\n   - **Advise on pain diary (timing, triggers, severity)**  \\n   - **Discuss long-term options (e.g., GnRH analogues if severe endometriosis)**  \\n\\n**Plan documented by: Dr. [Name], FY2**  \\n**Time: 1530 hours**  \\n**For: Consultant Gynaecology Review**  \\n\\n*(This is a fictional case for educational purposes only.)*\\n\\nCombined Guideline Analyses:\\n\\n\\n=== GUIDELINE 1: ESHRE Guideline: Endometriosis ===\\nHere is the analysis of the clinical note against the ESHRE 2022 Endometriosis Guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document detailed family history of endometriosis (especially given patient's early onset and recurrent disease).  \\n   Reason: Guideline emphasizes family history as a risk factor for adolescent/adult endometriosis (V. Endometriosis and adolescence section).  \\n\\n2. **Different management plan** - Consider adding **dienogest (progestogen)** as a first-line hormonal option instead of POP/Mirena trial, given stronger evidence for endometriosis-specific pain relief.  \\n   Reason: Guideline recommends progestogens (including dienogest) as first-line hormonal treatment for endometriosis-associated pain (II.1 Medical treatment section).  \\n\\n3. **Additional information needed** - Assess and document **quality of life impact** using a validated tool (e.g., EHP-30).  \\n   Reason: Guideline explicitly recommends QoL assessment in all symptomatic endometriosis cases (Introduction/Impact section).  \\n\\n### Somewhat Important Recommendations  \\n1. **Improved patient advice** - Provide detailed counseling about **long-term recurrence risks** (25% at 5 years) and need for potential extended hormonal suppression post-surgery.  \\n   Reason: Guideline highlights high recurrence rates and recommends long-term postoperative hormones (IV.2 Treatment of recurrent endometriosis).  \\n\\n2. **Different management plan** - Offer **GnRH antagonist (e.g., elagolix)** as second-line option if progestogens fail, with add-back therapy counseling.  \\n   Reason: Guideline recommends GnRH antagonists as second-line with bone protection (II.1 Medical treatment).  \\n\\n3. **Additional information needed** - Document explicit discussion about **fertility implications** (EFI score not calculated despite Stage II history).  \\n   Reason: Guideline stresses EFI use for fertility counseling (III. Endometriosis and infertility section).  \\n\\n### Less Important Recommendations  \\n1. **Improved patient advice** - Recommend **continuous NSAID regimen** during menses rather than PRN use.  \\n   Reason: Guideline shows better pain control with scheduled NSAIDs (II.1 Medical treatment).  \\n\\n2. **Additional information needed** - Consider **baseline bone density scan** if planning long-term hormonal suppression.  \\n   Reason: Guideline cautions about bone loss with prolonged GnRH/progestogen use (Safety sections).  \\n\\n3. **Different management plan** - Add **multidisciplinary pain team referral** now rather than waiting for persistence.  \\n   Reason: Guideline encourages early MDT involvement for chronic pain (II.6 Non-medical strategies).  \\n\\n### Unimportant Recommendations  \\n1. **Improved patient advice** - Suggest **gluten-free diet trial** given IBS overlap.  \\n   Reason: Guideline notes limited evidence for dietary interventions (II.6 section).  \\n\\n2. **Additional information needed** - Document cyclical **shoulder tip pain** screening for thoracic endometriosis.  \\n   Reason: Guideline mentions this but prevalence is very low (Extrapelvic sections).  \\n\\nKey omissions per guideline:  \\n- No discussion of **endometriosis malignancy risk** (absolute risk low but should be addressed)  \\n- Missing **explicit shared decision-making documentation** about surgery vs medical options  \\n- No reference to **center of expertise referral criteria** for potential deep endometriosis  \\n\\nThe note generally aligns well but could better address long-term planning, fertility preservation counseling, and standardized QoL metrics as emphasized in the 2022 updates.\\n\\n=== GUIDELINE 2: Guideline on Diagnosis and Management of Endometriosis ===\\nHere is the analysis of the clinical note against the ESHRE 2022 Endometriosis Guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations  \\n1. **Different management plan** - Consider adding **GnRH agonists with add-back therapy** as an option for hormonal suppression, given the contraindication to COCP (migraine with aura).  \\n   Reason: The guideline recommends GnRH agonists for endometriosis-associated pain, especially when COCP is contraindicated, and emphasizes add-back therapy to prevent bone loss (Section II.4).  \\n\\n2. **Additional information needed** - Document a **detailed discussion of surgical risks/benefits** if laparoscopy is planned, including ovarian reserve impact for future fertility.  \\n   Reason: The guideline highlights shared decision-making for surgery, especially regarding fertility implications (Recommendation 37, Section II.3).  \\n\\n3. **Improved patient advice** - Explicitly counsel on **fertility implications** of endometriosis and surgical options, given the patient’s reproductive age (G3P2).  \\n   Reason: The guideline stresses early discussion of fertility preservation (Recommendation 86) and avoiding ovarian suppression for infertility (Recommendation 39).  \\n\\n### Somewhat Important Recommendations  \\n1. **Different management plan** - Replace **naproxen** with **first-line NSAIDs** (e.g., ibuprofen) unless contraindicated, as evidence for specific NSAIDs is limited.  \\n   Reason: The guideline states NSAIDs may be offered but does not endorse specific agents (Section II.6).  \\n\\n2. **Additional information needed** - Include **Endometriosis Fertility Index (EFI)** assessment if fertility is a concern.  \\n   Reason: EFI is recommended for reproductive counseling (Section III.2).  \\n\\n3. **Improved patient advice** - Add **non-medical strategies** (e.g., acupuncture, pelvic floor physio) to counseling.  \\n   Reason: The guideline acknowledges potential benefits of adjunct therapies (Section II.6).  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Consider **MRI pelvis** now (not just if pain persists) to evaluate for deep infiltrating endometriosis.  \\n   Reason: MRI is recommended for deep endometriosis (Section II.2), but USS may suffice initially.  \\n\\n2. **Different management plan** - Specify **levonorgestrel-IUS (Mirena)** over POP as first-line hormonal option.  \\n   Reason: LNG-IUS has stronger evidence for pain reduction (Section II.4), but POP is acceptable.  \\n\\n### Unimportant Recommendations  \\n1. **Improved patient advice** - Suggest a **pain diary template** (e.g., digital app vs. paper).  \\n   Reason: While useful, the guideline does not specify methods (Good Practice Points).  \\n\\n2. **Additional information needed** - Add **CA-125** if monitoring for malignancy is clinically indicated.  \\n   Reason: Biomarkers are not recommended for diagnosis (Recommendation 75), but may be considered in complex cases.  \\n\\n### Key Omissions Addressed:  \\n- **Very Important**: Missing GnRH agonist/add-back option and fertility counseling.  \\n- **Somewhat Important**: EFI and non-medical strategies.  \\n- **Less Important**: Earlier MRI and LNG-IUS prioritization.  \\n\\nThe note largely aligns with guidelines but lacks emphasis on fertility preservation and optimal hormonal alternatives. Critical additions include GnRH agonists with add-back and explicit fertility discussions.\\n\\n=== GUIDELINE 3: The Initial Management of Chronic Pelvic Pain ===\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations  \\n1. **Additional information needed** - Document whether the patient was asked about past or present sexual assault.  \\n   Reason: The guideline emphasizes the importance of asking about sexual assault as it may be a contributing factor to chronic pelvic pain (GTG 2012 - Initial Mx of Chronic Pelvic Pain).  \\n\\n2. **Improved patient advice** - Provide more detailed counseling on self-management techniques and support organizations.  \\n   Reason: The guideline highlights the value of self-management techniques and support organizations for patients with chronic pelvic pain (GTG 2012).  \\n\\n3. **Different management plan** - Consider referral to a multidisciplinary pain team earlier, given the chronic nature and complexity of the pain.  \\n   Reason: The guideline recommends a comprehensive management plan involving multiple specialists for chronic pelvic pain (GTG 2012).  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Include a more detailed assessment of the patient’s level of function and set functional goals.  \\n   Reason: The guideline stresses the importance of establishing baseline function and setting goals for monitoring progress (GTG 2012).  \\n\\n2. **Improved patient advice** - Discuss the potential benefits and risks of GnRH analogues in more detail if considering them for severe endometriosis.  \\n   Reason: The guideline recommends thorough patient counseling on long-term treatment options (GTG 2012).  \\n\\n3. **Different management plan** - Consider adding antispasmodics more formally for IBS symptoms, given the patient’s history.  \\n   Reason: The guideline recommends antispasmodics for IBS-related pain (GTG 2012).  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Document whether the pain diary was provided and how it will be used in follow-up.  \\n   Reason: The guideline suggests pain diaries to identify triggers, but this is less critical than other factors (GTG 2012).  \\n\\n2. **Improved patient advice** - Include more details on dietary modifications for IBS management.  \\n   Reason: The guideline mentions dietary modifications as part of IBS management, but this is secondary to other interventions (GTG 2012).  \\n\\n### Unimportant Recommendations  \\n1. **Additional information needed** - Consider documenting the patient’s posture-related pain exacerbations, though this may not change management significantly.  \\n   Reason: The guideline notes the effect of posture on pain, but this is a minor detail in the overall assessment (GTG 2012).  \\n\\n2. **Improved patient advice** - Provide written information on pelvic floor exercises, though this is likely covered in the physio referral.  \\n   Reason: The guideline supports physiotherapy but does not mandate pre-referral patient education (GTG 2012).  \\n\\nThese recommendations aim to align the clinical note more closely with the GTG 2012 guideline, ensuring comprehensive and patient-centered care for chronic pelvic pain.\\n\\n=== GUIDELINE 4: Endometriosis: diagnosis and management ===\\nHere is the analysis of the clinical note against the NICE 2024 Endometriosis guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations  \\n1. **[Different management plan]** - **Consider MRI pelvis now (not just if pain persists) to assess for deep endometriosis involving bowel/bladder/ureter**  \\nReason: NICE recommends assessing extent of deep endometriosis with specialist-interpreted imaging (pelvic MRI or ultrasound) before operative laparoscopy for suspected deep endometriosis (Section 1.5). Given this patient's history of Stage II endometriosis and worsening symptoms, MRI should be prioritized.  \\n\\n2. **[Additional information needed]** - **Document whether patient is currently trying to conceive, as this significantly impacts management options**  \\nReason: NICE emphasizes tailoring treatment based on fertility priorities (Section 1.11). Hormonal treatment alone is not recommended for women trying to conceive, and surgical approaches differ.  \\n\\n### Somewhat Important Recommendations  \\n1. **[Improved patient advice]** - **Provide detailed information about all hormonal options (POP, Mirena IUS, GnRH analogues) including efficacy, side effects, and impact on fertility**  \\nReason: NICE stresses discussing benefits/risks of all options based on patient preferences (Section 1.8, 1.10). The note mentions hormonal suppression but lacks shared decision-making details.  \\n\\n2. **[Different management plan]** - **Explicitly consider excision (not ablation) if endometrioma found on future imaging**  \\nReason: NICE recommends excision over ablation for endometriomas to improve pregnancy chances (Section 1.10). This should be specified given her reproductive age.  \\n\\n3. **[Additional information needed]** - **Assess for bowel/bladder symptoms (e.g., dyschezia, hematuria) that may suggest deep infiltrating endometriosis**  \\nReason: NICE requires evaluation of deep endometriosis symptoms (Section 1.3). The history focuses on pain but misses other key symptoms.  \\n\\n### Less Important Recommendations  \\n1. **[Improved patient advice]** - **Provide written information/resources about endometriosis support groups and pain management programs**  \\nReason: NICE highlights the need for information/support interventions (Research Recommendations). While not critical, this improves patient experience.  \\n\\n2. **[Different management plan]** - **Consider earlier MDT involvement (pain team) given chronicity of symptoms**  \\nReason: NICE recommends multidisciplinary care for complex cases (Section 1.1). Earlier input may prevent prolonged suffering.  \\n\\n### Unimportant Recommendations  \\n1. **[Additional information needed]** - **Document migraine aura frequency/severity to better assess COCP contraindication**  \\nReason: While relevant for hormonal options, this is less critical than fertility status or deep endometriosis evaluation.  \\n\\n2. **[Improved patient advice]** - **Suggest specific dietary modifications for IBS/endometriosis overlap**  \\nReason: NICE notes lifestyle interventions need more research (Research Recommendations). Current evidence is weak.  \\n\\nKey Missing Elements per NICE:  \\n- No documentation of systematic laparoscopic inspection plan (should specify trained surgeon)  \\n- No discussion of fertility-preserving surgical options  \\n- Incomplete pain characterization (missing dyschezia/cyclic urinary symptoms)  \\n\\nThe note generally aligns well but would benefit from deeper endometriosis evaluation and more patient-centered counseling about long-term management options.\\n\\n=== GUIDELINE 5: Management of Unscheduled Bleeding on Hormone Replacement Therapy (HRT) ===\\n### Analysis of Clinical Note vs. BMS Guideline on Unscheduled Bleeding on HRT\\n\\nThe clinical note describes a **32-year-old AFAB patient with chronic pelvic pain (CPP)**, a history of endometriosis, and prior COCP use (discontinued due to migraine with aura). However, the **BMS guideline focuses on managing unscheduled bleeding in patients on HRT**, which does not directly apply to this case since:\\n1. The patient is **not currently on HRT** (discontinued COCP in 2022).\\n2. The primary complaint is **chronic pelvic pain**, not unscheduled bleeding.\\n\\nThus, **most recommendations in the BMS guideline are not directly relevant**. However, some general principles can be considered:\\n\\n---\\n\\n### Somewhat Important Recommendations  \\n**Additional information needed** - **Clarify if the patient has any unscheduled bleeding episodes** (even if not on HRT)  \\nReason: While the patient is not on HRT, the guideline emphasizes assessing bleeding patterns in women with pelvic pain to rule out endometrial pathology.  \\n\\n**Improved patient advice** - **If considering future HRT (e.g., for endometriosis management), counsel on bleeding risks and progestogen options**  \\nReason: The guideline highlights the importance of progestogen selection (e.g., LNG-IUD) for endometrial protection if HRT is reintroduced.  \\n\\n---\\n\\n### Less Important Recommendations  \\n**Different management plan** - **If HRT is restarted (e.g., POP/Mirena), document a plan for managing unscheduled bleeding**  \\nReason: The guideline recommends monitoring and adjusting HRT if bleeding occurs.  \\n\\n---\\n\\n### Unimportant Recommendations  \\n**Additional information needed** - **Document BMI and smoking status more prominently if HRT is reconsidered**  \\nReason: The guideline lists these as minor risk factors for endometrial cancer with HRT use.  \\n\\n---\\n\\n### Summary  \\nThe **BMS guideline is not directly applicable** to this case, as the patient is not on HRT and the primary issue is CPP. However, if HRT is reintroduced (e.g., for endometriosis), the guideline’s recommendations on bleeding management and progestogen selection become relevant.  \\n\\n**Key Missing Element:** The note does not mention unscheduled bleeding, which is the focus of the BMS guideline. If such bleeding were present, further investigations (e.g., TVS, endometrial biopsy) per the guideline would be warranted.  \\n\\n**Final Note:** This clinical note aligns well with general gynecological practice for CPP but does not intersect significantly with the BMS HRT bleeding guideline.\\n\\nPlease extract and consolidate actionable suggestions from these multiple guideline analyses. Create combined suggestions when multiple guidelines recommend similar interventions, and prioritize suggestions based on clinical importance and consensus across guidelines. For each suggestion, include detailed context with relevant quoted text from the supporting guidelines.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts multiple clinical guideline analyses into structured, actionable suggestions. You will receive analyses from multiple guidelines and must create a comprehensive set of suggestions that prioritizes the most important recommendations while avoiding redundancy.\\n\\nYour task is to analyze the provided guideline analyses and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nMULTI-GUIDELINE PROCESSING PRINCIPLES:\\n- Combine and consolidate similar recommendations from different guidelines\\n- Prioritize recommendations that appear in multiple guidelines or are emphasized as critical\\n- Avoid duplicate suggestions - if multiple guidelines suggest the same thing, create one combined suggestion referencing all relevant guidelines\\n- When guidelines conflict, clearly note this and explain the rationale for your recommendation\\n- Organize suggestions by clinical priority and relevance to the case\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"combinedSuggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guidelines in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"sourceGuidelines\\\": [\\\"Guideline 1 Name\\\", \\\"Guideline 2 Name\\\"],\\n      \\\"consolidatedFrom\\\": \\\"explanation of how this suggestion combines recommendations from multiple guidelines, if applicable\\\"\\n    }\\n  ],\\n  \\\"guidelinesSummary\\\": [\\n    {\\n      \\\"guidelineTitle\\\": \\\"Guideline Name\\\",\\n      \\\"keyRecommendations\\\": \\\"summary of the most important recommendations from this guideline for this case\\\",\\n      \\\"relevanceScore\\\": \\\"high|medium|low\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for consolidation:\\n- If multiple guidelines recommend the same intervention, create ONE suggestion that references all relevant guidelines\\n- Prioritize suggestions that are consistently recommended across multiple guidelines\\n- When guidelines provide different specifics for the same general recommendation, include the most comprehensive/specific version\\n- If guidelines conflict, choose the most appropriate recommendation for this specific case and explain why\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the relevant guidelines using quotation marks\\n- Reference which specific guidelines support this recommendation\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\",\n  \"transcript_length\": 3882,\n  \"guidelines_count\": 5,\n  \"guideline_titles\": [\n    \"ESHRE Guideline: Endometriosis\",\n    \"Guideline on Diagnosis and Management of Endometriosis\",\n    \"The Initial Management of Chronic Pelvic Pain\",\n    \"Endometriosis: diagnosis and management\",\n    \"Management of Unscheduled Bleeding on Hormone Replacement Therapy (HRT)\"\n  ]\n}\n\nA: {\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Consider trial of hormonal suppression (e.g., progestogen-only pill (POP) or Mirena IUS) given contraindication to COCP\",\n      \"suggestedText\": \"Consider trial of hormonal suppression with dienogest (progestogen) or levonorgestrel-IUS (Mirena) as first-line options, given contraindication to COCP. Discuss GnRH agonists with add-back therapy as second-line if first-line fails.\",\n      \"context\": \"Multiple guidelines recommend specific hormonal options for endometriosis-associated pain. ESHRE 2022 states 'progestogens (including dienogest) as first-line hormonal treatment for endometriosis-associated pain' and recommends GnRH antagonists as second-line. NICE 2024 emphasizes discussing all hormonal options' benefits/risks. This is appropriate given the patient's confirmed endometriosis history and COCP contraindication.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's recommendation for dienogest as first-line and NICE's emphasis on comprehensive hormonal counseling, plus ESHRE's suggestion of GnRH antagonists as second-line\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Consider diagnostic laparoscopy if refractory\",\n      \"suggestedText\": \"Consider diagnostic laparoscopy with systematic inspection by trained surgeon if refractory, with explicit discussion of fertility implications and excision (not ablation) if endometriomas found\",\n      \"context\": \"ESHRE 2022 and NICE 2024 both emphasize the importance of surgical planning for endometriosis. NICE specifically recommends 'systematic laparoscopic inspection by trained surgeon' and 'excision over ablation for endometriomas'. This is appropriate given the patient's Stage II history and reproductive age.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined NICE's surgical recommendations with ESHRE's fertility counseling emphasis\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Repeat TV USS if pain persists\",\n      \"suggestedText\": \"Arrange MRI pelvis now (not just if pain persists) to assess for deep infiltrating endometriosis, given history of Stage II disease and worsening symptoms\",\n      \"context\": \"NICE 2024 recommends 'assessing extent of deep endometriosis with specialist-interpreted imaging (pelvic MRI or ultrasound) before operative laparoscopy'. ESHRE also notes MRI's value for deep endometriosis. This is indicated due to worsening symptoms and prior Stage II diagnosis.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined NICE's strong recommendation for early MRI with ESHRE's imaging guidance\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Gynae clinic in 4/52 for reassessment\",\n      \"suggestedText\": \"Gynae clinic in 4/52 with: 1) QoL assessment (EHP-30), 2) fertility intentions documentation, 3) bowel/bladder symptom screening, and 4) MDT pain team referral\",\n      \"context\": \"ESHRE 2022 recommends 'QoL assessment in all symptomatic endometriosis cases'. NICE 2024 requires 'evaluation of deep endometriosis symptoms' and emphasizes fertility status. Both guidelines support MDT involvement. This comprehensive approach addresses multiple guideline priorities for this chronic pain case.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's QoL metrics, NICE's symptom screening, and both guidelines' MDT recommendations\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Discuss long-term options (e.g., GnRH analogues if severe endometriosis)\",\n      \"suggestedText\": \"Provide detailed counseling on: 1) all hormonal options' efficacy/side effects, 2) fertility implications (calculate EFI if needed), 3) long-term recurrence risks (25% at 5 years), and 4) malignancy risk (though low)\",\n      \"context\": \"ESHRE 2022 stresses 'fertility counseling (EFI use)' and 'long-term postoperative hormones'. NICE 2024 emphasizes 'shared decision-making about all options'. This is critical for informed consent in this reproductive-age patient with recurrent disease.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE's fertility/risk discussions with NICE's shared decision-making focus\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Pelvic physio referral (if musculoskeletal component suspected)\",\n      \"suggestedText\": \"Refer to pelvic physio now (not just if MSK suspected) and consider multidisciplinary pain team referral given chronicity\",\n      \"context\": \"GTG 2012 chronic pelvic pain guideline recommends 'early MDT involvement for complex pain'. ESHRE also encourages 'non-medical strategies'. This is appropriate given 6+ month pain duration and limited response to current analgesics.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"The Initial Management of Chronic Pelvic Pain\", \"ESHRE Guideline: Endometriosis\"],\n      \"consolidatedFrom\": \"Combined GTG's early MDT recommendation with ESHRE's adjunct therapy suggestions\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"No documentation of sexual assault screening\",\n      \"suggestedText\": \"Document screening for past/present sexual assault as part of comprehensive pain assessment\",\n      \"context\": \"GTG 2012 guideline emphasizes 'asking about sexual assault as it may contribute to chronic pelvic pain'. This is a sensitive but important aspect of holistic pain management.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"The Initial Management of Chronic Pelvic Pain\"],\n      \"consolidatedFrom\": \"Direct from GTG guideline recommendation\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Ibuprofen 400mg TDS PRN\",\n      \"suggestedText\": \"Scheduled NSAID regimen during menses (e.g., ibuprofen 400mg TDS) rather than PRN use\",\n      \"context\": \"ESHRE 2022 shows 'better pain control with scheduled NSAIDs' for endometriosis. This simple change may improve cyclical pain management.\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\"],\n      \"consolidatedFrom\": \"Direct from ESHRE guideline\"\n    },\n    {\n      \"id\": \"9\",\n      \"originalText\": \"No baseline bone density documentation\",\n      \"suggestedText\": \"Consider baseline bone density scan if planning long-term hormonal suppression (e.g., GnRH analogues)\",\n      \"context\": \"ESHRE 2022 cautions about 'bone loss with prolonged GnRH/progestogen use'. NICE also notes bone protection needs. This is precautionary given potential long-term hormone use.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"sourceGuidelines\": [\"ESHRE Guideline: Endometriosis\", \"NICE Endometriosis: diagnosis and management\"],\n      \"consolidatedFrom\": \"Combined ESHRE and NICE bone health considerations\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"ESHRE Guideline: Endometriosis\",\n      \"keyRecommendations\": \"1) Progestogens (dienogest) as first-line hormonal treatment 2) QoL assessment with EHP-30 3) Fertility counseling with EFI 4) Scheduled NSAIDs for pain\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"NICE Endometriosis: diagnosis and management\",\n      \"keyRecommendations\": \"1) Early MRI for deep endometriosis 2) Shared decision-making about all options 3) Excision over ablation for endometriomas 4) Systematic laparoscopic inspection\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"The Initial Management of Chronic Pelvic Pain\",\n      \"keyRecommendations\": \"1) Sexual assault screening 2) Early MDT involvement 3) Functional goal setting\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"BMS Guideline on Unscheduled Bleeding on HRT\",\n      \"keyRecommendations\": \"Not directly applicable (patient not on HRT)\",\n      \"relevanceScore\": \"low\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 5431\nCompletion tokens: 2003\nTotal tokens: 7434\nEstimated cost: $0.003717",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 5431,
    "completion_tokens": 2003,
    "total_tokens": 7434,
    "estimated_cost_usd": 0.003717
  }
}